Ribavirin and interferon-β synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines

被引：183

作者：

Morgenstern, B

Michaelis, M

Baer, PC

Doerr, HW

Cinatl, J

机构：

[1] Univ Frankfurt, Inst Med Virol, D-60596 Frankfurt, Germany

[2] Univ Frankfurt, Inst Nephrol, Dept Internal Med 4, D-60596 Frankfurt, Germany

来源：

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS | 2005年 / 326卷 / 04期

关键词：

human primary epithelial kidney cells; Caco2; CL14; MA104; Vero;

D O I：

10.1016/j.bbrc.2004.11.128

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Initial in vitro investigations demonstrated type I interferons (IFNs: IFN-alpha, IFN-beta) to inhibit replication of SARS coronavirus (SARS-CoV), but found the nucleoside analogue ribavirin ineffective in Vero cells. In this report, ribavirin was shown to inhibit SARS-CoV replication in five different cell types of animal or human origin at therapeutically achievable concentrations. Since clinical anti-SARS-CoV activity of type I interferons or ribavirin is limited, we investigated the combination of IFN-beta and ribavirin. Determination of the virus yield indicated highly synergistic anti-SARS-CoV action of the combination suggesting the consideration of ribavirin plus IFN-beta for the treatment of SARS. (C) 2004 Elsevier Inc. All rights reserved.

引用

收藏

页码：905 / 908

页数：4

相关论文

共 16 条

[1] Isolation of proximal and distal tubule cells from human kidney by immunomagnetic separation [J].

Baer, PC ;

Nockher, WA ;

Haase, W ;

Scherberich, JE .

KIDNEY INTERNATIONAL, 1997, 52 (05) :1321-1331

[2] In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds [J].

Chen, F ;

Chan, KH ;

Jiang, Y ;

Kao, RYT ;

Lu, HT ;

Fan, KW ;

Cheng, VCC ;

Tsui, WHW ;

Hung, IFN ;

Lee, TSW ;

Guan, Y ;

Peiris, JSM ;

Yuen, KY .

JOURNAL OF CLINICAL VIROLOGY, 2004, 31 (01) :69-75

[3] QUANTITATIVE-ANALYSIS OF DOSE-EFFECT RELATIONSHIPS - THE COMBINED EFFECTS OF MULTIPLE-DRUGS OR ENZYME-INHIBITORS [J].

CHOU, TC ;

TALALAY, P .

ADVANCES IN ENZYME REGULATION, 1984, 22 :27-55

[4] Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings [J].

Chu, CM ;

Cheng, VCC ;

Hung, IFN ;

Wong, MML ;

Chan, KH ;

Chan, KS ;

Kao, RYT ;

Poon, LLM ;

Wong, CLP ;

Guan, Y ;

Peiris, JSM ;

Yuen, KY .

THORAX, 2004, 59 (03) :252-256

[5] Treatment of SARS with human interferons [J].

Cinatl, J ;

Morgenstern, B ;

Bauer, G ;

Chandra, P ;

Rabenau, H ;

Doerr, HW .

LANCET, 2003, 362 (9380) :293-294

[6] Role of interferons in the treatment of severe acute respiratory syndrome [J].

Cinatl, J ;

Michaelis, M ;

Scholz, M ;

Doerr, HW .

EXPERT OPINION ON BIOLOGICAL THERAPY, 2004, 4 (06) :827-836

[7] Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus [J].

Cinatl, J ;

Morgenstern, B ;

Bauer, G ;

Chandra, P ;

Rabenau, H ;

Doerr, HW .

LANCET, 2003, 361 (9374) :2045-2046

[8] Identification of a novel coronavirus in patients with severe acute respiratory syndrome [J].

Drosten, C ;

Günther, S ;

Preiser, W ;

van der Werf, S ;

Brodt, HR ;

Becker, S ;

Rabenau, H ;

Panning, M ;

Kolesnikova, L ;

Fouchier, RAM ;

Berger, A ;

Burguière, AM ;

Cinatl, J ;

Eickmann, M ;

Escriou, N ;

Grywna, K ;

Kramme, S ;

Manuguerra, JC ;

Müller, S ;

Rickerts, V ;

Stürmer, M ;

Vieth, S ;

Klenk, HD ;

Osterhaus, ADME ;

Schmitz, H ;

Doerr, HW .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (20) :1967-1976

[9]

Festi D, 2004, WORLD J GASTROENTERO, V10, P12

[10] Retroviral vectors pseudotyped with severe acute respiratory syndrome coronavirus S protein [J].

Giroglou, T ;

Cinatl, J ;

Rabenau, H ;

Drosten, C ;

Schwalbe, H ;

Doerr, HW ;

von Laer, D .

JOURNAL OF VIROLOGY, 2004, 78 (17) :9007-9015